HWHG(SH:600079) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-11-13 05:12Group 1 - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has registered the Phase II clinical trial for HW231019 tablets, aimed at evaluating its efficacy and safety for postoperative pain relief after abdominal surgery [1] - The trial is a multicenter, randomized, double-blind, parallel, placebo-controlled study, with the objective to explore the efficacy and safety of HW231019 tablets and to preliminarily investigate its dosage for postoperative pain [1] - HW231019 tablets received approval for clinical trials in March 2025 for the treatment of acute pain, and the cumulative R&D investment in this project has reached approximately 20 million RMB [1] Group 2 - Currently, there is one company in the same target and type of drug for acute pain that has entered Phase II/III clinical stages, four companies in Phase II, and two companies in Phase I clinical stages [1] - The company emphasizes that drug registration requires completion of clinical trials and approval from the National Medical Products Administration before market launch, highlighting the lengthy and uncertain nature of drug development [2]